Pharmacokinetics,plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration |
| |
| Authors: | A Goudah S Hasabelnaby |
| |
| Institution: | 1. Department of Veterinary Pharmacology and Toxicology, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab, India;2. Dept. of Veterinary Pharmacology and Toxicology, Dr. G.C. Negi College of Veterinary and Animal Sciences, CSK H.P. Agricultural University, Palampur, H.P., India;3. Institute of Computational Comparative Medicine, College of Veterinary Medicine, P222A, Mosier Hall, Kansas State University, Manhattan KS-66506. USA;1. AstraZeneca R&D, Safety Pharmacology, Alderley Park, UK;2. AstraZeneca R&D, Computational Toxicology, Safety Assessment, Mölndal, Sweden;3. AstraZeneca R&D, Global DMPK Centre of Excellence, Södertälje, Sweden;4. AstraZeneca R&D, Discovery Sciences, Alderley Park, UK;5. AstraZeneca R&D, Modeling & Simulation, Drug Metabolism & Pharmacokinetics (DMPK), Alderley Park, UK |
| |
| Abstract: | In this study the disposition kinetics and plasma availability of moxifloxacin in Muscovy ducks after single intravenous (i.v.), intramuscular (i.m.) and oral (p.o.) administrations of 5 mg kg?1 b.wt. were investigated. The concentrations of moxifloxacin in the plasma were measured using high-performance liquid chromatography (HPLC) with fluorescence detection on samples collected at frequent intervals after drug administration. Following intravenous injection, the decline in plasma drug concentration was bi-exponential with half-lives of (t1/2α) 0.22 ± 0.10 h and (t1/2β) 2.49 ± 0.26 h for distribution and elimination phases, respectively. The volume of distribution at steady-state (Vdss) was 1.02 ± 0.14 l kg?1 and the total body clearance (Cltot) was 0.32 ± 0.11 l kg?1 h?1, respectively. After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (Cmax) were 2.38 ± 0.43 and 2.11 ± 0.36 μg ml?1 and were obtained at 1.47 ± 0.26 and 1.83 ± 0.16 h (Tmax), respectively, the elimination half-lives (T1/2el) were 3.14 ± 0.42 and 2.63 ± 0.44 h, respectively, and AUC0–24 were 15.87 ± 2.35 and 14.52 ± 2.37 μg ml?1 h?1, respectively. The systemic bioavailabilities were 96.36 ± 11.54% and 86.79 ± 12.64%, respectively. In vitro plasma protein binding percent was 32%. We concluded that moxifloxacin might be clinically interesting alternative for the treatment of most sensitive bacterial infections in Muscovy ducks. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
